861 eyes of 794 patients were included. Patients in each group got 3 intravitreal anti- VEGF injections and were followed up for six months during which visual acuity and macular thickness on OCT were analysed. Mean macular OCT thickness in Bevacizumab group decreased from 526μm to 261 μm. Mean OCT thickness of macula in Ranibizumab group reduced from 416 µm to 219 μm. There was no significant difference between two groups in terms of final VA and side effects.